TABLE 1

Cytokine inhibitors licensed for the treatment of rheumatoid arthritis

TargetGeneric NameTrade NameAdministration RouteStandard Dose and FrequencyHalf-Life
TNFInfliximabRemicadeaIntravenous3 mg/kg weeks 0, 2, 6, then 8 weekly8–10 days
AdalimumabHumirabSubcutaneous40 mg every 2 weeks2 weeks (mean terminal half-life)
EtanerceptEnbrelcSubcutaneous25 mg 2×/week or 50 mg 1×/week70 hours (mean elimination half-life)
GolimumabSimponiaSubcutaneous50 mg monthly12 ± 3 days
CertolizumabCimziadSubcutaneous400 mg weeks 0, 2, 4, then 200 mg fortnightly14 days (terminal elimination phase half-life)
IL-6RTocilizumabRoactemrae, actemrafIntravenous or subcutaneous8 mg/kg every 4 weeks13 days
IL-1RAnakinraKineretSubcutaneous100 mg daily3–6 hours
  • a Janssen Biotech, Titusville, NJ.

  • b AbbVie, Chicago, IL.

  • c Amgen, Thousand Oaks, CA.

  • d UCB Inc., Atlanta, GA.

  • e Roche, Basel, Switzerland.

  • f Genentech, South San Francisco, CA.